Global Chemotherapy Market Overview

Introduction

Global chemotherapy market was valued at around USD 24,169 million in 2018 and is expected to grow with the CAGR of 5.9 % during forecast period 2019-2026.

Global Chemotherapy Market, 2016-2026 (USD Million)

Market Dynamics    

Chemotherapy is drug therapy used in the treatment of cancer. Chemotherapy prevents cancer cells from growing and it does this by killing the dividing cells. When chemotherapy drugs travel through the bloodstream to reach cells throughout the body, it is called as systemic and when drugs are directed towards a particular area of the body it is named as regional chemotherapy. It can treat various types of cancer including leukemia, breast cancer, sarcoma, lung cancer, ovarian cancer, lymphoma and many others. Despite chemotherapy is widely used treatment it has number of side effects as therapy also damages healthy cells. It shows side effects such as hair loss, nausea, vomiting, hearing impairment, fatigue, loss of appetite, mucositis and other. As per American Cancer Society statistics given for 2017, there will be an estimated 1,688,780 new cancer cases diagnosed and 600,920 cancer deaths in the US.

The growing prevalence of different types of cancer, rising exposure of people to carcinogenic agents and sedentary lifestyles are the major factors driving the growth of chemotherapy market. Furthermore, the advancement in technology, surging attention to research and development in the field of oncology and gove
ment supportive programmes boost the growth of the market. Moreover, awareness among population and upgrading healthcare infrastructure is anticipated support the growth of chemotherapy market. However, unaffordable treatment cost and unfavourable reimbursement procedures in the developing countries may act as deterrent causing sluggish growth of the market.

Segment Analysis

The global chemotherapy market is segmented based on drugs, types, route of drug administration, and end-user. Based on drugs, it is segmented into alkylating agents, anti-tumor antibiotics, antimetabolites, topoisomerase inhibitors, mitotic inhibitors, and others. Alkylating agents are further segmented into alkyl sulfonates, mustard gas derivatives, ethylenimines, hydrazines and triazines, and others. Anti-tumor antibiotics are further segmented into chromomycin and anthracyclines.  Topoisomerase inhibitors are further segmented into Topoisomerase I inhibitors and Topoisomerase II inhibitors. On the basis of types, the market is segmented into blood cancer, lung cancer, lymphatic cancer, breast cancer, ovarian cancer, myeloma, and others. On the basis of route of drug administration, the market is segmented into oral and parenteral.  Based on end-user, it is segmented into hospitals& clinics, research institutes, and others.

 

Global Chemotherapy Market, By Region

Regional Analysis

Geographically, the global chemotherapy market is segmented into five major regions: North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa. The chemotherapy market in American region is enforced by upsurge in affected population, existence of key market players producing chemotherapy drugs and growing expenses on healthcare facilities. Besides, drastically changing lifestyle, high consumption of alcohol and smoking habits propels the market growth. National expenditure for cancer care in the US came up near about $ 125 billion in 2010 and could reach $ 156 billion by 2020. Europe chemotherapy market is affected by expanding number of pharmaceutical companies committed to research and gove
ment supportive activities for R&D. Asia-Pacific market is anticipated to be the fastest growing region attributed to growing geriatric population, rising demand for chemotherapy drugs, rapidly growing healthcare industry and presence of well-qualified and trained healthcare professionals such as oncologist. LAMEA is expected to witness steady growth in this market.

Key Players

Sanofi, Novartis, Eli Lilly & Company, Pfizer Inc., AstraZeneca, GlaxoSmithKline, Teva Pharmaceuticals Industries, Bristol-Myers Squibb, Bayer AG, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Boehringer Ingelheim, and others.

Recent Development

In 2019, Smart-pill maker Proteus Digital Health has launched an oral chemotherapy equipped with its ingestible sensor, which aims to help oncologists track treatment effectiveness and adherence in the cancer patients.

Additionally, AbbVie one of the leading pharmaceutical company announces US FDA approval of VENCLEXTA (venetoclax) as a chemotherapy-free combination regimen for traditionally untreated chronic lymphocytic leukemia patients.

Global Chemotherapy Market Segmentation

Global Chemotherapy Market by Type

Alkylating Agents 

Alkyl Sulfonates

Mustard Gas Derivatives

Ethylenimines

Hydrazines

Triazines

Anti-Tumor Antibiotics

Chromomycin

anthracyclines

Antimetabolites

Topoisomerase Inhibitors

Topoisomerase I inhibitors

Topoisomerase II inhibitors

Mitotic Inhibitors

Global Chemotherapy Market By Types

Blood Cancer

Lung Cancer

Lymphatic Cancer

Breast Cancer

Ovarian Cancer

Myeloma

Route of Drug Administration

Oral

Parenteral

Global Chemotherapy Market End Users

Hospitals & Clinics

Research Institutes

Others

Key Market Players

Sanofi

Novartis

Eli Lilly & Company

Pfizer Inc.

AstraZeneca

GlaxoSmithKline

Teva Pharmaceuticals Industries

Bristol-Myers Squibb

Bayer AG

F. Hoffmann-La Roche Ltd

Merck & Co., Inc.

Boehringer Ingelheim